A lawsuit filed by Pfizer Inc. against Johnson & Johnson over its defensive contracting for Remicade (infliximab) will be a significant commercial test for the US biosimilar market. The complaint could have implications for how far brand manufacturers can go when it comes to protecting their blockbuster franchises through payer contracts, and whether or not biosimilars will have the chance to make substantial inroads in competitive markets.
Pfizer announced Sept. 20 that it filed suit against J&J in the US District Court of Eastern Pennsylvania over what...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?